<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03298633</url>
  </required_header>
  <id_info>
    <org_study_id>ICSI/IVF-NSMI</org_study_id>
    <nct_id>NCT03298633</nct_id>
  </id_info>
  <brief_title>ICSI Versus Conventional IVF in Couples With Non-severe Male Infertility</brief_title>
  <acronym>ICSI/IVF-NSMI</acronym>
  <official_title>Intracytoplasmic Sperm Injection (ICSI) Versus Conventional in Vitro Fertilization (IVF) in Couples With Non-severe Male Infertility: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jie Qiao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Peace Maternity and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Haidian Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, parallel-controlled(1:1 treatment ratio), open-label, randomized clinical&#xD;
      trials regarding fertilization and pregnancy outcomes between ICSI and conventional IVF among&#xD;
      couples with no-severe male-factor infertility in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, large-scale, randomized controlled clinical trial will enroll 2,346 couples&#xD;
      with non-severe male infertility undergoing their first or second cycle of IVF or ICSI. The&#xD;
      study will recruit participants from 6 Reproductive Medical Centers across mainland China.The&#xD;
      participation in this study will be approximately 2 years with a total of 7 visits from&#xD;
      controlled ovarian hyperstimulation, pregnancy to delivery. On the day of oocyte retrieval,&#xD;
      eligible participants will be allocated to two groups at a ratio of 1:1- ICSI protocol, and&#xD;
      conventional IVF protocol. All participants will be randomized through stratified block&#xD;
      randomization according to the study sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">March 31, 2023</completion_date>
  <primary_completion_date type="Actual">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients that have provided informed consent will be randomized to either ICSI or conventional IVF. Randomization and allocation of patients to study groups will be performed on the day of oocyte retrieval. Stratified permuted block randomization will be centrally controlled by administrative staffs in the trial center, who are not involved in the treatment procedure. When there is an eligible participant to be enrolled into the study, nurses from the specific site will login the trial system to get allocation of patients according to a computer-generated randomization list in a 1:1 ratio, with a variable block size of 2, 4 or 8 and stratified by center.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The blinding method in out study is open-label in general. However, in order to avoid psychological effect for participants and unexpected drop-off, the trial is designed to inform participants their insemination method on the day of fresh embryo transfer or the day of embryo freezing. Prior to this, randomization will be strictly performed and keep secret to participants and clinicians.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy leading to live birth after the first cycle with embryo transfer</measure>
    <time_frame>After 22 weeks of gestation</time_frame>
    <description>A delivery of one or more living infants (≥22 weeks gestation or birth weight more than 1,000g).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization</measure>
    <time_frame>16-20 hours after oocyte retrieval</time_frame>
    <description>Number of zygotes with 2 PN (per oocyte retrieved and per women randomized).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fertilization failure</measure>
    <time_frame>72 hours after oocyte retrieval</time_frame>
    <description>No oocyte formed 2 PN in this given cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Available embryo</measure>
    <time_frame>72 hours after oocyte retrieval</time_frame>
    <description>Number of embryos ≥4 cells and ≤30% fragmentation on day 3 observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good quality embryo</measure>
    <time_frame>72 hours after oocyte retrieval</time_frame>
    <description>Number of embryos with ≥6 cells and ≤30% fragmentation developed from 2PN embryos on day 3 observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation</measure>
    <time_frame>28 days after embryo transfer</time_frame>
    <description>Number of gestational sacs observed per embryo transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>7 weeks after embryo transfer</time_frame>
    <description>One or more observed gestational sac or definitive clinical signs of pregnancy under ultrasonography at 7 weeks after embryo transfer (including clinically documented ectopic pregnancy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy</measure>
    <time_frame>7 weeks after embryo transfer</time_frame>
    <description>Pregnancy with two or more gestational sacs or positive heart beats at 7 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>Presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate/severe ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>From date of controlled ovarian hyperstimulation until the date of oocyte retrieval, assessed about 14-16 days.</time_frame>
    <description>exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate, or severe according to the degree of abdominal distention, ovarian Enlargement, and respiratory, hemodynamic, and metabolic complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>22 weeks of gestation</time_frame>
    <description>Spontaneous loss of an intra-uterine pregnancy prior to 22 completed weeks of gestational age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic pregnancy</measure>
    <time_frame>7 weeks of gestation</time_frame>
    <description>Implantation takes place outside the uterine cavity, confirmed by sonography or laparoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational diabetes mellitus (GDM)</measure>
    <time_frame>24-37 weeks of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive disorders of pregnancy</measure>
    <time_frame>28-37 weeks of pregnancy</time_frame>
    <description>Comprising pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antepartum haemorrhage</measure>
    <time_frame>28-37 weeks of pregnancy</time_frame>
    <description>Including placenta previa, placenta accreta and unexplained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>28-37 weeks of pregnancy</time_frame>
    <description>Birth of a fetus delivered after 28 and before 37 completed weeks of gestational age in participants confirmed ongoing pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Within 2 weeks after live birth</time_frame>
    <description>Including low birth weight (defined as weight &lt; 2500 gm at birth), very low birth weight (defined as &lt; 1500 gm at birth), high birth weight (defined as &gt;4000 gm at birth) and very high birth weight (defined as &gt;4500 gm at birth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large for gestational age</measure>
    <time_frame>Within 2 weeks after live birth</time_frame>
    <description>Birth weight &gt;90th centile for gestation, based on standardised ethnicity based charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age</measure>
    <time_frame>Within 2 weeks after live birth</time_frame>
    <description>Less than 10th centile for gestational age at delivery based on standardised ethnicity based charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital anomaly</measure>
    <time_frame>Within 2 weeks after live birth</time_frame>
    <description>Any congenital anomaly will be included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality</measure>
    <time_frame>Within 6 weeks after live birth</time_frame>
    <description>Fetal or neonatal death occurring during late pregnancy (at 28 completed weeks of gestational age and later), during childbirth, or up to seven completed days after birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>Within 6 weeks after live birth</time_frame>
    <description>death of a live born baby within 28 days of birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2387</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Intracytoplasmic Sperm Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional IVF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ICSI</intervention_name>
    <description>All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.</description>
    <arm_group_label>Intracytoplasmic Sperm Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional IVF</intervention_name>
    <description>All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.</description>
    <arm_group_label>Conventional IVF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infertile couples scheduled for their first or second IVF/ICSI cycle.&#xD;
&#xD;
          -  Men with non-severe male infertility: Sperm concentration 5,000,000-15,000,000/ml or&#xD;
             sperm with progressive motility (type A+B) 10-32%.&#xD;
&#xD;
          -  Women received either gonadotrophin-releasing hormone agonist protocol or&#xD;
             gonadotrophin-releasing hormone antagonist protocol as their controlled ovarian&#xD;
             hyperstimulation treatment.&#xD;
&#xD;
          -  Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Couple with contraindication for IVF or ICSI.&#xD;
&#xD;
          -  Couples receiving donor sperm or donor eggs.&#xD;
&#xD;
          -  Couples undergoing PGD and PGS.&#xD;
&#xD;
          -  Sperm concentration with progressive motility used for insemination &lt;100,000/ml on the&#xD;
             day of oocyte retrieval.&#xD;
&#xD;
          -  Women with 0 oocytes after oocyte retrieval.&#xD;
&#xD;
          -  Using frozen semen.&#xD;
&#xD;
          -  Poor fertilization in previous cycle (≤ 25%).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Qiao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haidian Maternal and Child Health Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Peace Maternity and Child Health Hospital of Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2023</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>July 25, 2023</last_update_submitted>
  <last_update_submitted_qc>July 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Jie Qiao</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Male infertility</keyword>
  <keyword>In vitro fertilization</keyword>
  <keyword>Intracytoplasmic sperm injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03298633
org study id: ICSI/IVF-NSMI
nct id: NCT03298633
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
A multicenter, parallel-controlled(1:1 treatment ratio), open-label, randomized clinical
      trials regarding fertilization and pregnancy outcomes between ICSI and conventional IVF among
      couples with no-severe male-factor infertility in China.
A multicenter, large-scale, randomized controlled clinical trial will enroll 2,346 couples
      with non-severe male infertility undergoing their first or second cycle of IVF or ICSI. The
      study will recruit participants from 6 Reproductive Medical Centers across mainland China.The
      participation in this study will be approximately 2 years with a total of 7 visits from
      controlled ovarian hyperstimulation, pregnancy to delivery. On the day of oocyte retrieval,
      eligible participants will be allocated to two groups at a ratio of 1:1- ICSI protocol, and
      conventional IVF protocol. All participants will be randomized through stratified block
      randomization according to the study sites.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Eligible patients that have provided informed consent will be randomized to either ICSI or conventional IVF. Randomization and allocation of patients to study groups will be performed on the day of oocyte retrieval. Stratified permuted block randomization will be centrally controlled by administrative staffs in the trial center, who are not involved in the treatment procedure. When there is an eligible participant to be enrolled into the study, nurses from the specific site will login the trial system to get allocation of patients according to a computer-generated randomization list in a 1:1 ratio, with a variable block size of 2, 4 or 8 and stratified by center.
primary purpose: Treatment
masking: None (Open Label)
masking description: The blinding method in out study is open-label in general. However, in order to avoid psychological effect for participants and unexpected drop-off, the trial is designed to inform participants their insemination method on the day of fresh embryo transfer or the day of embryo freezing. Prior to this, randomization will be strictly performed and keep secret to participants and clinicians.
measure: Ongoing pregnancy leading to live birth after the first cycle with embryo transfer
time frame: After 22 weeks of gestation
description: A delivery of one or more living infants (≥22 weeks gestation or birth weight more than 1,000g).
measure: Fertilization
time frame: 16-20 hours after oocyte retrieval
description: Number of zygotes with 2 PN (per oocyte retrieved and per women randomized).
measure: Total fertilization failure
time frame: 72 hours after oocyte retrieval
description: No oocyte formed 2 PN in this given cycle.
measure: Available embryo
time frame: 72 hours after oocyte retrieval
description: Number of embryos ≥4 cells and ≤30% fragmentation on day 3 observation.
measure: Good quality embryo
time frame: 72 hours after oocyte retrieval
description: Number of embryos with ≥6 cells and ≤30% fragmentation developed from 2PN embryos on day 3 observation.
measure: Implantation
time frame: 28 days after embryo transfer
description: Number of gestational sacs observed per embryo transferred.
measure: Clinical pregnancy
time frame: 7 weeks after embryo transfer
description: One or more observed gestational sac or definitive clinical signs of pregnancy under ultrasonography at 7 weeks after embryo transfer (including clinically documented ectopic pregnancy).
measure: Multiple pregnancy
time frame: 7 weeks after embryo transfer
description: Pregnancy with two or more gestational sacs or positive heart beats at 7 weeks of gestation.
measure: Ongoing pregnancy
time frame: 12 weeks after embryo transfer
description: Presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.
measure: Moderate/severe ovarian hyperstimulation syndrome (OHSS)
time frame: From date of controlled ovarian hyperstimulation until the date of oocyte retrieval, assessed about 14-16 days.
description: exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate, or severe according to the degree of abdominal distention, ovarian Enlargement, and respiratory, hemodynamic, and metabolic complications.
measure: Miscarriage
time frame: 22 weeks of gestation
description: Spontaneous loss of an intra-uterine pregnancy prior to 22 completed weeks of gestational age.
measure: Ectopic pregnancy
time frame: 7 weeks of gestation
description: Implantation takes place outside the uterine cavity, confirmed by sonography or laparoscopy.
measure: Gestational diabetes mellitus (GDM)
time frame: 24-37 weeks of pregnancy
measure: Hypertensive disorders of pregnancy
time frame: 28-37 weeks of pregnancy
description: Comprising pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia.
measure: Antepartum haemorrhage
time frame: 28-37 weeks of pregnancy
description: Including placenta previa, placenta accreta and unexplained.
measure: Preterm birth
time frame: 28-37 weeks of pregnancy
description: Birth of a fetus delivered after 28 and before 37 completed weeks of gestational age in participants confirmed ongoing pregnancy.
measure: Birth weight
time frame: Within 2 weeks after live birth
description: Including low birth weight (defined as weight < 2500 gm at birth), very low birth weight (defined as < 1500 gm at birth), high birth weight (defined as >4000 gm at birth) and very high birth weight (defined as >4500 gm at birth).
measure: Large for gestational age
time frame: Within 2 weeks after live birth
description: Birth weight >90th centile for gestation, based on standardised ethnicity based charts.
measure: Small for gestational age
time frame: Within 2 weeks after live birth
description: Less than 10th centile for gestational age at delivery based on standardised ethnicity based charts.
measure: Congenital anomaly
time frame: Within 2 weeks after live birth
description: Any congenital anomaly will be included.
measure: Perinatal mortality
time frame: Within 6 weeks after live birth
description: Fetal or neonatal death occurring during late pregnancy (at 28 completed weeks of gestational age and later), during childbirth, or up to seven completed days after birth.
measure: Neonatal mortality
time frame: Within 6 weeks after live birth
description: death of a live born baby within 28 days of birth
arm group label: Intracytoplasmic Sperm Injection
arm group type: Active Comparator
description: On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
arm group label: Conventional IVF
arm group type: Active Comparator
description: On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
intervention type: Other
intervention name: ICSI
description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
arm group label: Intracytoplasmic Sperm Injection
intervention type: Other
intervention name: Conventional IVF
description: All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
arm group label: Conventional IVF
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jie Qiao, M.D.
role: Study Director
affiliation: Peking University Third Hospital
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: China
responsible party type: Sponsor-Investigator
investigator affiliation: Peking University Third Hospital
investigator full name: Jie Qiao
investigator title: President
mesh term: Infertility
mesh term: Infertility, Male
sharing ipd: No